Wells Fargo raises Abbvie stock price target to $340 on pipeline
Covered in this story
What has happened since
- AbbVie is up 1.9% since this was published, 10 days ago.
- Wells Fargo is down 0.2% since this was published, 10 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Wells Fargo’s $340 target on $ABBV is on the record and being tracked to Nov 2027 (12-month default), scored on the close that day.
Wells Fargo’s track record →Analyst targets on AbbVie
- RBC Capital Markets: at $289 · target $330 by Nov 2027 · Outperform via Investing.com
- UBS: at $276 · target $275 by Oct 2027 · Neutral via GuruFocus
- Bank of America: at $262 · target $289 by Sep 2027 · Buy via AOL.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 49 stories mentioning AbbVie, the earliest published 16 May 2017.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.